How to Evaluate Past FDA Inspection Outcomes When Selecting Principal Investigators

Introduction: Why PI Inspection History Matters

Past performance is often the best predictor of future risk. In clinical trials, one of the most critical factors during site feasibility is the Principal Investigator’s (PI) history with regulatory inspections—particularly those conducted by the U.S. Food and Drug Administration (FDA). Sponsors, CROs, and quality teams are increasingly required to review and consider a PI’s inspection track record as part of the site qualification process, especially in light of ICH-GCP E6(R2) emphasis on quality risk management.

This article provides a detailed guide to identifying, interpreting, and integrating FDA inspection outcomes into PI selection, with real-world examples, data sources, and sponsor SOP recommendations.

1. Types of FDA Inspections and Their Relevance

The FDA conducts several types of inspections under its Bioresearch Monitoring (BIMO) Program:

• Routine Surveillance Inspections: To evaluate PI compliance in ongoing or completed studies
• For-Cause Inspections: Triggered by safety signals, data anomalies, or complaints
• Pre-Approval Inspections (PAIs): For sites contributing pivotal efficacy/safety data
• Risk-Based Inspections: Based on historical findings or therapeutic area risk

Each inspection may result in a Form FDA 483, Establishment Inspection Report (EIR), or enforcement actions such as Warning Letters or Disqualification Notices.

2. Key Regulatory Documents to Review

When assessing PI history, sponsors should gather and review:

• Publicly available FDA Form 483s (https://www.fda.gov/inspections)
• Warning Letters (https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations)
• Clinical Investigator Disqualification Proceedings (https://www.fda.gov/ICECI/EnforcementActions)
• Information via Freedom of Information Act (FOIA) if needed
• Internal sponsor audit records and historical monitoring notes

Note: While not all inspection outcomes are public, redacted summaries can still be used for compliance screening.

3. Common Findings Noted During PI Inspections

When PIs receive Form 483s or Warning Letters, the following are among the most cited issues:

• Failure to follow the investigational plan/protocol
• Inadequate recordkeeping or missing source data
• Failure to report adverse events or SAEs in a timely manner
• Improper informed consent documentation
• Failure to personally supervise the conduct of the study
• Drug accountability discrepancies

Each of these represents a potential risk if selecting the same PI for future studies.

4. How to Access and Search Inspection Records

To check a PI’s history, sponsors may:

• Search by PI name or site name in FDA’s Inspection Classification Database
• Request Form 483 copies using FOIA
• Review investigator inspection history provided during feasibility questionnaire
• Use ClinicalTrials.gov to identify trials the PI was involved in and cross-reference against inspection data

Not all FDA inspections are made public; therefore, sponsor-collected inspection records are also critical.

5. Scoring and Interpretation of Inspection Outcomes

Sponsors may use a scoring system to rate PIs based on inspection risk. Sample categories:

These scores can be included in overall site feasibility or risk assessment tools.

6. Case Study: Site Screening Impacted by Past FDA Warning Letter

Scenario: A Phase III site submitted a feasibility response with strong recruitment metrics. However, further due diligence revealed the PI had received a Warning Letter two years earlier for failure to maintain accurate drug accountability records and improperly delegating safety assessments.

Outcome: The sponsor excluded the site based on risk matrix scoring and flagged the PI in its internal CTMS. An alternate investigator from the same institution was selected after satisfactory audit review.

7. Sponsor SOPs for Inspection History Screening

To institutionalize risk-based PI evaluation, sponsors should include inspection review in:

• Feasibility questionnaire templates
• Site selection SOPs and checklists
• Investigator qualification visit (IQV) forms
• TMF documentation plans for risk justification

All PI selection rationales should be documented and justifiable during regulatory inspections.

8. Internal Tracking of PI Inspection Data

Sponsors and CROs should maintain internal records of all PI inspections, including:

• Dates and type of inspection (e.g., PAI, for-cause)
• Findings (e.g., observation types)
• Corrective and preventive actions (CAPA) taken
• Current status (resolved/unresolved)
• QA recommendations regarding future trial suitability

This data can be stored within the CTMS or a sponsor inspection management system.

9. When Past Findings May Be Acceptable

Not all prior observations disqualify a PI. Context matters. Acceptable factors include:

• Findings were minor and well-remediated
• No repeat observations in subsequent inspections
• Robust CAPA plans and staff retraining completed
• Recent audits show improved compliance

In such cases, the PI may be considered with conditions (e.g., enhanced monitoring).

Conclusion

Assessing past FDA inspection outcomes is an essential step in modern PI and site selection processes. It protects trial integrity, reduces regulatory risk, and demonstrates due diligence in accordance with ICH-GCP. By integrating inspection history into feasibility assessments and applying structured review criteria, sponsors and CROs can make informed decisions, improve study outcomes, and ensure compliance in an increasingly complex regulatory landscape.